UNITED STATES SECURITIES AND EXCHANGE COMMISSION November 1, 2017

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Oasmia Pharmaceutical AB

File No. 1-37604 - CF#35499

Oasmia Pharmaceutical AB submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 20-F filed on August 24, 2017, as amended.

Based on representations by Oasmia Pharmaceutical AB that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 4.32 through June 9, 2022 Exhibit 4.33 through June 9, 2022

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary